Multiple myeloma maintenance therapy duration
Web19 feb. 2024 · Median time to first response was 0.77 months (range, 0.1-2.1), and the median duration of response was not estimable. Median time to ≥CR was 7.36 months (range, 2.8-18.5); median duration of ≥CR was not estimable. MRD negativity (10 ‒5) at the end of induction occurred in 3 (18.8%) patients; none were MRD negative at 10 –6. Web25 nov. 2024 · At a median follow-up of 35.4 months from second randomization, median progression-free survival was not reached in the daratumumab maintenance arm vs 46.7 months in the observation group (HR = 0.53, 95% CI = 0.42–0.68, P < .0001), showing superiority of the addition of daratumumab as maintenance therapy.
Multiple myeloma maintenance therapy duration
Did you know?
Web15 ian. 2024 · There is some debate about the optimal length of maintenance therapy in today's myeloma world. Most European doctors will have a fixed duration (2-3 years) of maintenance therapy but that could be related to approvals by European regulatory agencies. ... For more information on the importance of maintenance therapy, learn … Web13 apr. 2024 · Chimeric antigen receptor (CAR) T cells have dramatically improved the outcomes of patients with certain relapsed and/or refractory haematological …
WebAcum 1 zi · As Faiman points out, in 2014, the International Myeloma Working Group had added patients with at least 60% BMPCs, FLCratio equal to or greater than 100, and … Web21 feb. 2024 · The ideal duration of maintenance therapy remains unknown, and the current recommendation is to continue maintenance until disease progression, particularly in patients with high-risk disease. Digital Features This article is published with digital features, including a summary slide, to facilitate understanding of the article.
Web20 mai 2024 · The median duration of lenalidomide maintenance was 21 months, with 25% of patients receiving <11 months of maintenance and 25% with treatment longer … Web11 oct. 2024 · Patients with MM who are within 12 months of ASCT and without progression from diagnosis are eligible. Patients may enroll any time after induction (registration step …
Web26 nov. 2024 · He concludes by saying that fixed duration therapy has not proven to be superior to continuous therapy, which has contributed to a median PFS of more than 5 years and a median OS of more than 10 years, and we still do not know how to best individualize therapy.3 References (11) D’Souza A & Lonial S.
traa board of directorsWebMaintenance therapy post autologous stem cell transplant (ASCT) is commonly employed in myeloma patients to prolong remission, as relapse invariably occurs after ASCT. … traac pottstown paWebHowever, a significant increase in second primary malignancy has been recently reported in ASCT patients receiving lenalidomide maintenance vs. observation in the Myeloma XI … tra accepted apartments in hudson countyWeb23 mar. 2024 · Drugs in Phase 1 Trials Becoming More Effective, No Less Fatal. By. Andrea S. Blevins Primeau, PhD, MBA. March 22, 2024. Response rates improved from 2000 to 2024, but the rate of treatment ... thermostat\u0027s 9lWebAcum 2 zile · The HRs were 0.576, 0.615, and 0.740 in patients aged 65 or younger, 65 to 75 years, and 75 years or older, respectively. Regarding frailty subgroups, PFS benefit was seen regardless of status ... traacs800Web16 apr. 2024 · In the IFM 2005-02 trial, the median duration of lenalidomide maintenance administration was approximately 2 years, while in the CALGB 100104 and GIMEMA RV-MM-PI-209 trials, it was 2.5 and 3 years, respectively [ 33 ]. Whether fixed-duration maintenance results in improved outcomes versus treatment until progression is … traa crewWebIntroduction. Plasma cell myeloma is a clonal disorder of malignant plasma cells and is a disease of the elderly, with a median age of onset of 70 years. 1,2 Development of newer therapeutic agents over the last decade has led to improvements in survival in younger patients; 3,4 however, such benefits have yet to be realized in the very elderly (>80 … traacs chromium